Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis. / Eiberg, Mads Frederik; Rezahosseini, Omid; Bukan, Katrine Brandt; Charlotte Arp, Bodil; Le, Vivian Bui; Ahmad, Faiza; Howitz, Michael; Lendorf, Maria; Friborg, Jeppe; Lindegaard, Birgitte; Harboe, Zitta Barrella.

I: Vaccine, 2024.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Eiberg, MF, Rezahosseini, O, Bukan, KB, Charlotte Arp, B, Le, VB, Ahmad, F, Howitz, M, Lendorf, M, Friborg, J, Lindegaard, B & Harboe, ZB 2024, 'Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis', Vaccine. https://doi.org/10.1016/j.vaccine.2024.05.021

APA

Eiberg, M. F., Rezahosseini, O., Bukan, K. B., Charlotte Arp, B., Le, V. B., Ahmad, F., Howitz, M., Lendorf, M., Friborg, J., Lindegaard, B., & Harboe, Z. B. (Accepteret/In press). Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis. Vaccine. https://doi.org/10.1016/j.vaccine.2024.05.021

Vancouver

Eiberg MF, Rezahosseini O, Bukan KB, Charlotte Arp B, Le VB, Ahmad F o.a. Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis. Vaccine. 2024. https://doi.org/10.1016/j.vaccine.2024.05.021

Author

Eiberg, Mads Frederik ; Rezahosseini, Omid ; Bukan, Katrine Brandt ; Charlotte Arp, Bodil ; Le, Vivian Bui ; Ahmad, Faiza ; Howitz, Michael ; Lendorf, Maria ; Friborg, Jeppe ; Lindegaard, Birgitte ; Harboe, Zitta Barrella. / Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis. I: Vaccine. 2024.

Bibtex

@article{00ffb173031743b7a4e64d6bf1e8aea5,

title = "Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis",

abstract = "Background: Pneumonia is one of the main contributors to non-cancer mortality among patients with head and neck cancer (HNC). This study aimed to determine the vaccine uptake for pneumococcal polysaccharide and conjugate vaccines, quadrivalent influenza vaccines, and mRNA COVID-19 vaccines before and after an HNC diagnosis. Furthermore, the study investigated the timing of vaccination after a cancer diagnosis. Materials & methods: This register based multicentre study included Danish patients ≥ 18y diagnosed with HNC between 2018 and 2021. The vaccine uptake was assessed by calculating cumulative incidence (CI), while the timing of vaccination after an HNC diagnosis was explored by calculating incidence rates of vaccination the first and second half year after a cancer diagnosis. Results: The cumulative incidence of vaccine uptake for pneumococcal vaccines was estimated to be 8 % and 16 % one year before and after an HNC diagnosis, respectively. The CIs were 36 % and 38 % for quadrivalent influenza vaccines, respectively, whereas the CIs of vaccine uptake for mRNA COVID-19 vaccines were 60 % and 89 %. The IR of mRNA COVID-19 vaccinations the first half year after HNC diagnosis were 273 per 1000 person-months of follow-up (PMFU) and 111 per 1000 PMFU the second half year, respectively (IRR: 0.38, p < 0.001). Comparing the same periods, the IR of quadrivalent influenza vaccination was 28 per 1000 PMFU and 51 per 1000 PMFU (IRR: 1.95, 0 < 0.001). The IRs of pneumococcal vaccinations were 11 per 1000 PMFU and 14 per 1000 PMFU (IRR 1.28, p = 0.21). Conclusions: Although our study shows a significant increase in pneumococcal and COVID-19 vaccine uptake after HNC diagnosis, a gap remains in vaccine uptake before diagnosis, underscoring the need for increased awareness of vaccination options and recommendations. Our findings could serve as a reference for future recommendations.",

keywords = "COVID-19, Influenza, Neoplasms, S. Pneumoniae, Vaccine uptake",

author = "Eiberg, {Mads Frederik} and Omid Rezahosseini and Bukan, {Katrine Brandt} and {Charlotte Arp}, Bodil and Le, {Vivian Bui} and Faiza Ahmad and Michael Howitz and Maria Lendorf and Jeppe Friborg and Birgitte Lindegaard and Harboe, {Zitta Barrella}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s)",

year = "2024",

doi = "10.1016/j.vaccine.2024.05.021",

language = "English",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis

AU - Eiberg, Mads Frederik

AU - Rezahosseini, Omid

AU - Bukan, Katrine Brandt

AU - Charlotte Arp, Bodil

AU - Le, Vivian Bui

AU - Ahmad, Faiza

AU - Howitz, Michael

AU - Lendorf, Maria

AU - Friborg, Jeppe

AU - Lindegaard, Birgitte

AU - Harboe, Zitta Barrella

PY - 2024

Y1 - 2024

N2 - Background: Pneumonia is one of the main contributors to non-cancer mortality among patients with head and neck cancer (HNC). This study aimed to determine the vaccine uptake for pneumococcal polysaccharide and conjugate vaccines, quadrivalent influenza vaccines, and mRNA COVID-19 vaccines before and after an HNC diagnosis. Furthermore, the study investigated the timing of vaccination after a cancer diagnosis. Materials & methods: This register based multicentre study included Danish patients ≥ 18y diagnosed with HNC between 2018 and 2021. The vaccine uptake was assessed by calculating cumulative incidence (CI), while the timing of vaccination after an HNC diagnosis was explored by calculating incidence rates of vaccination the first and second half year after a cancer diagnosis. Results: The cumulative incidence of vaccine uptake for pneumococcal vaccines was estimated to be 8 % and 16 % one year before and after an HNC diagnosis, respectively. The CIs were 36 % and 38 % for quadrivalent influenza vaccines, respectively, whereas the CIs of vaccine uptake for mRNA COVID-19 vaccines were 60 % and 89 %. The IR of mRNA COVID-19 vaccinations the first half year after HNC diagnosis were 273 per 1000 person-months of follow-up (PMFU) and 111 per 1000 PMFU the second half year, respectively (IRR: 0.38, p < 0.001). Comparing the same periods, the IR of quadrivalent influenza vaccination was 28 per 1000 PMFU and 51 per 1000 PMFU (IRR: 1.95, 0 < 0.001). The IRs of pneumococcal vaccinations were 11 per 1000 PMFU and 14 per 1000 PMFU (IRR 1.28, p = 0.21). Conclusions: Although our study shows a significant increase in pneumococcal and COVID-19 vaccine uptake after HNC diagnosis, a gap remains in vaccine uptake before diagnosis, underscoring the need for increased awareness of vaccination options and recommendations. Our findings could serve as a reference for future recommendations.

AB - Background: Pneumonia is one of the main contributors to non-cancer mortality among patients with head and neck cancer (HNC). This study aimed to determine the vaccine uptake for pneumococcal polysaccharide and conjugate vaccines, quadrivalent influenza vaccines, and mRNA COVID-19 vaccines before and after an HNC diagnosis. Furthermore, the study investigated the timing of vaccination after a cancer diagnosis. Materials & methods: This register based multicentre study included Danish patients ≥ 18y diagnosed with HNC between 2018 and 2021. The vaccine uptake was assessed by calculating cumulative incidence (CI), while the timing of vaccination after an HNC diagnosis was explored by calculating incidence rates of vaccination the first and second half year after a cancer diagnosis. Results: The cumulative incidence of vaccine uptake for pneumococcal vaccines was estimated to be 8 % and 16 % one year before and after an HNC diagnosis, respectively. The CIs were 36 % and 38 % for quadrivalent influenza vaccines, respectively, whereas the CIs of vaccine uptake for mRNA COVID-19 vaccines were 60 % and 89 %. The IR of mRNA COVID-19 vaccinations the first half year after HNC diagnosis were 273 per 1000 person-months of follow-up (PMFU) and 111 per 1000 PMFU the second half year, respectively (IRR: 0.38, p < 0.001). Comparing the same periods, the IR of quadrivalent influenza vaccination was 28 per 1000 PMFU and 51 per 1000 PMFU (IRR: 1.95, 0 < 0.001). The IRs of pneumococcal vaccinations were 11 per 1000 PMFU and 14 per 1000 PMFU (IRR 1.28, p = 0.21). Conclusions: Although our study shows a significant increase in pneumococcal and COVID-19 vaccine uptake after HNC diagnosis, a gap remains in vaccine uptake before diagnosis, underscoring the need for increased awareness of vaccination options and recommendations. Our findings could serve as a reference for future recommendations.

KW - COVID-19

KW - Influenza

KW - Neoplasms

KW - S. Pneumoniae

KW - Vaccine uptake

U2 - 10.1016/j.vaccine.2024.05.021

DO - 10.1016/j.vaccine.2024.05.021

M3 - Journal article

C2 - 38789370

AN - SCOPUS:85194196606

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -

ID: 393841303